Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Immuno-Grade Bradykinin Receptor 2 Antibodies

Close filters
No results were found for the filter!
Rabbit Monoclonal
NEW
B2 [UMB12] (RM-IHC-Grade-Bradykinin Receptor 2 Antibody), Rabbit Monoclonal
B2 [UMB12] (RM-IHC-Grade-Bradykinin Receptor 2...
The non-phospho-B2 Bradykinin Receptor antibody is directed against the distal end of the carboxyl-terminal tail of human B2. It can be used to detect total B2 receptors in Western blots independent of phosphorylation. The B2 antibody...
CHF495.00 *
Details
Citations
KO-Validated
Immunohistochemical identification of Bradykinin Receptor 2 in pancreatic islets
B2 (IHC-grade), Bradykinin Receptor 2 Antibody
The B2 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human B2. It can be used to detect total B2 receptors in Western blots independent of phosphorylation. The B2 antibody can also be used to...
CHF400.00 *
Details

Bradykinin receptor 2 (B2) are activated by the endogenous peptides bradykinin (BK) and Lys-BK (kallidin). Bradykinin is a vasoactive, pain inducing and pro-inflammatory kinin released during acute inflammation, and its receptors, B1 and B2, are expressed on eosinophils, and neutrophils.The B2 antagonist Icatibant (Firazyr) is approved in the US and EU for the treatment of acute attacks of hereditary angioedema.

Bradykinin receptor 2 (B2) are activated by the endogenous peptides bradykinin (BK) and Lys-BK (kallidin). Bradykinin is a vasoactive, pain inducing and pro-inflammatory kinin released during... read more »
Close window
Immuno-Grade Bradykinin Receptor 2 Antibodies

Bradykinin receptor 2 (B2) are activated by the endogenous peptides bradykinin (BK) and Lys-BK (kallidin). Bradykinin is a vasoactive, pain inducing and pro-inflammatory kinin released during acute inflammation, and its receptors, B1 and B2, are expressed on eosinophils, and neutrophils.The B2 antagonist Icatibant (Firazyr) is approved in the US and EU for the treatment of acute attacks of hereditary angioedema.

Recently viewed